KLR
Kailera Therapeutics (KLRA) Q2 2026 Earnings
KLRA·Reported May 26, 2026·Before market open
Diluted EPS came in at $-3650.00, missed the $-0.78 consensus by $3649.22.
Diluted EPS
$-3650.00missed by $3649.22
Consensus: $-0.78
Financial Snapshot
Trailing eight quarters through Q2 2026 — latest period from 8-K press release; updates when 10-Q/10-K is filed
Q2 2026 Earnings FAQ
Common questions about Kailera Therapeutics 's Q2 2026 earnings report.
Kailera Therapeutics (KLRA) reported Q2 2026 earnings on May 26, 2026 before market open.
Kailera Therapeutics reported diluted EPS of $-3650.00 for Q2 2026.
EPS missed the consensus estimate of $-0.78 by $3649.22.
You can read the 8-K earnings release (0001193125-26-239362) directly on SEC EDGAR. The filing index links above go to sec.gov.